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ABSTRACT:
The expression level of the HER family is unreliable as a predictive marker for targeted 
therapies in cancer. Thus, there is a need to develop other biomarkers, which can 
be used to accurately select responsive patients for targeted therapies. The HER 
dimerization status may be more important than HER receptor expression per se in 
determining sensitivity or resistance to a given therapeutic agent. The aim of the study 
is to develop a FRET assay using dye conjugated secondary antibodies to assess HER 
receptor dimerization. Using primary antibodies from different species in conjunction 
with Alexa488 and Alexa546 conjugated secondary antibodies, we validated our 
EGFR/HER2 dimerization assay in three cell lines, EGFR positive A431 cells as well as 
HER2 positive breast cell lines BT474 and SKBR3 cells. Finally, we applied our assay to 
assess EGFR/HER2 dimerization in paraffin embedded cell pellets. Our results show 
promise for the assay to be applied to tumor samples in order to assess the prognostic 
significance and predictive value of HER receptor dimerization in various cancers.
INTRODUCTION
Dysregulation of HER (ErbB) receptors has been 
implicated in several cancers. For example, EGFR is 
frequently over-expressed in Head and Neck Squamous 
Cell Carcinoma (HNSCC) and is correlated with poor 
disease-free survival and overall survival in these patients 
[1, 2]. In breast cancer, over-expression and amplification 
of HER2 occurs in about 15-20% of breast cancer and 
is predictive of poor outcome in these patients [3-5]. 
Trastuzumab (Herceptin) was developed to target HER2 
proteins and has been shown to increase the survival of 
patients [6, 7]. However, the response rate for Herceptin 
monotherapy for advanced breast cancer patients is 
only around 35% and all responders eventually develop 
resistance to Herceptin [8]. In lung cancers, EGFR 
mutations were found to predict an excellent response to 
EGFR TKIs but these are only found in a small number 
of patients [9, 10]. Furthermore, such mutations are 
uncommon in other cancers like HNSCC and may not 
be predictive of sensitivity to EGFR inhibitors in these 
cancers [11]. For those cancers without EGFR mutations, 
it has been shown that the expression levels of EGFR do 
not predict the success of these drugs and the response 
rate to these inhibitors remains poor [9, 12]. One reason 
for this is that the HER receptors are able to form 
alternative dimers and can therefore compensate the loss 
of function of one receptor during targeted therapies [13, 
14]. Thus, the HER receptor dimerization patterns may be 
more important than the expression level per se in cancer 
prognosis and prediction of response to targeted therapies 
[15, 16]. Therefore, the ability to assess the dimerization 
pairs within tumours could be useful as a prognostic or 
predictive biomarker for targeted therapies in cancer. 
In cell lines co-immunoprecipitation (IP) can 
be used to make an assessment of HER dimerization. Oncotarget 2011; 2:  728 - 736 729 www.impactjournals.com/oncotarget
However, this method is not ideal since the two HER 
proteins assessed may not have interacted with each 
other directly but through a tertiary protein. Assessment 
of HER dimerization states in tumours has also been 
proven  to  be  difficult  since  the  conventional  method 
utilizing IHC can only assess the expression levels and 
their co-localization of HER receptors. For example, in 
EGFR and HER2 staining, the percentage of stained cells 
and their intensity allows us to assess EGFR and HER2 
expression in the tumors. However, staining for both 
receptors in a single sample can only reveal intercellular 
co-localization but this does not provide a true indication 
of their dimerization states. The same limitation applies to 
intensity-based fluorescence/confocal microscopy, which 
can reveal intracellular co-localization but not definitively 
demonstrate the existence of HER dimers.
We hypothesized that HER dimerization could be 
quantified by Förster Resonance Energy Transfer (FRET) 
after successfully applying the assay to assess EGFR 
activation states in tissue microarrays [17]. Previously, we 
conjugated primary antibodies to a pair of fluorophores. 
However, such experiments often resulted in a waste of 
large amount of antibodies during the primary antibody 
conjugation process and thus was not economically viable. 
Here we propose and test the use of a pair of commercially 
available  fluorophore-labeled  secondary  antibodies 
specific  for  different  species  of  primary  to  conduct  a 
FRET experiment. This protocol could potentially be 
applied to assess various HER receptor dimerization 
and other protein interactions by varying the primary 
antibodies. Our aim is to apply the assay to assess EGFR/
HER2 dimerization in HER2 positive breast tumors as 
well as EGFR over-expressing tumors like HNSCC. As 
a proof of principle, we have validated our assay for the 
dimerization of EGFR and HER2 in 3 cell lines; HER2 
positive cell lines BT474 and SKBr3 as well as EGFR 
positive A431 cells, in relation to ligand stimulation and 
targeted therapies. We also applied the assay to paraffin-
embedded cell pellets to demonstrate the robustness of 
the assay and the potential clinical application to tissue 
microarrays (TMA). 
RESULTS
Using primary antibodies for EGFR and HER2 
from two different species in conjunction with species-
specific secondary antibodies conjugated to Alexa488 or 
Alexa546, we first assessed the dimerization of EGFR and 
HER2 in fixed cell samples. The schematic diagram is for 
this labeling is shown in Figure 1. We established that there 
is an advantage in utilizing the over-expressed receptor 
as the FRET donor (data not shown). For example, in 
EGFR over-expressing cell lines where we chose EGFR 
as the donor, we used a mouse-EGFR antibody with an 
anti-mouse Alexa488 secondary antibody. HER2 would 
be the acceptor, so we would use a rabbit-HER2 antibody 
with an anti-rabbit Alexa546 secondary antibody. It was 
hypothesized that upon ligand simulation, there would be 
an increase in EGFR/HER2 dimerization and thus FRET 
between the two conjugated flurophores, The overlap in 
the donor (Alexa488) emission spectrum and acceptor 
(Alexa546) absorption spectrum allows FRET to occur, 
resulting  in  a  decrease  of  donor  fluorescence  lifetime, 
indicative  of  EGFR/HER2  dimerization  (Figure  1).  In 
HER2 over-expressing cell lines, we used a rabbit-HER2 
antibody with an anti-rabbit Alexa488 secondary antibody 
as donor and a mouse-EGFR antibody with an anti-mouse 
Alexa546 secondary antibody as acceptor to assess EGFR/
HER2 dimerization by FRET.
To show in-situ that EGFR/HER2 dimerization could 
Figure 1: Schematic Diagram of EGFR/HER2 dimerization by FRET utilizing Alexa-conjugated secondary antibodies.Oncotarget 2011; 2:  728 - 736 730 www.impactjournals.com/oncotarget
be monitored by our assay, BT474 cells were stimulated 
with HER ligands, either EGF or heregulin as well as 
by  an  EGFR-specific  tyrosine  kinase  inhibitor,  Iressa. 
Firstly, we stained unstimulated BT474 cells with only 
the primary rabbit-HER2 antibody and the correlating 
anti-rabbit Alexa488 secondary antibody (as described 
in Materials and Methods). The lifetime measured in this 
sample gives us the fluorescence lifetime of Alexa 488, 
which was shown to have a mean value of approximately 
2.35 ns (Figure 2A). When the cells were stained with both 
the primary antibodies (anti-HER2 and anti-EGFR) as 
well as the appropriate species-specific labeled secondary 
antibodies, we found a statistically significant decrease in 
fluorescence donor lifetime to around 2.25 ns (P<0.025) 
compared to that with the donor alone (Figure 2A), 
suggesting the existence of a basal level of EGFR/HER2 
dimerization, as confirmed by immunoprecipitation and 
western blot (Figure 2D). 
When BT474 cells were treated with EGF, there 
was a further decrease in donor lifetime to 2.12 ns 
which is statistically significant compared to the result 
from  unstimulated  cells  (P<0.025)  (Figure  2A),  which 
correlated with the higher amount of EGFR-HER2 
dimerization seen in IP (Figure 2D). As a negative control, 
BT474 cells were stimulated with heregulin (HRG), which 
induces dimerization of HER3 and HER4, with their 
preferred dimerization partner HER2 [18]. Therefore, 
this might be seen to decrease EGFR/HER2 dimerization 
(Figure 2A), which was confirmed by IP (Figure 2D). To 
further demonstrate the specificity of our assay, another 
negative control was used. EGFR specific tyrosine kinase 
inhibitor gefitinib (Iressa), which was shown to decrease 
basal EGFR/HER2 dimerization (Figure 2D), produced 
an increase in donor fluorescence lifetime when compared 
to that of untreated cells (P<0.005) (Figure 2A). A visual 
representation of the distribution of fluorescence lifetimes 
across typical cells, using a pseudo-colour display, 
ranging from 1.40 – 3.00 ns, is shown in Figure 2C. The 
image for EGF treated cells shows almost entirely ‘blue’ 
pixels compared to the blue/yellow combination seen in 
the  control,  or  yellow/green  combination  in  HRG  and 
Iressa treated cells. Each image is accompanied by a 
graphical representation of these lifetimes. In the case of 
EGF-treated cells, this distribution is seen to shift towards 
lower lifetimes, compared to the control or HRG and 
Iressa treated cells.
Figure 2B represents fluorescence images of these 
cells with HER2 shown in green and EGFR in yellow. 
Figure 2: Assessment of EGFR/HER2 dimerization by FRET in BT474 cells.
A. BT474 cells were stimulated with different ligands, EGF and HRG (both 100ng/ml for 10 min) or pre-treated with Iressa 1µM for 1 hour 
before being fixed for FRET experiments (see Methods). Analysis was performed globally across each group of cells using a bi-exponential 
fit and interpreting the slower component as the fluorescence lifetime (See Supplementary Figure 1) (n=20 for each condition) B. Panels of 
fluorescence microscopy images are shown for each of these conditions illustrating EGFR (lower panels) and HER2 (upper panels) receptor 
localization. C. As in A, a bi-exponential fit and the slow components were used. Here, fits were performed on a pixel-by-pixel basis and 
used to generate pseudo-colour fluorescence lifetime images, with a scale from 1.4 ns to 3.0 ns, showing the distribution of fluorescence 
lifetimes across the cells. The corresponding histograms are generated from the relative frequency of lifetimes across this range thus 
showing the shifts that occur between treatment conditions. D. Co-immunoprecipitation blots for EGFR and HER2 on BT474 cell lysate 
for the different conditions as described in A. Oncotarget 2011; 2:  728 - 736 731 www.impactjournals.com/oncotarget
As  can  be  seen  here,  the  shortcoming  of  fluorescence 
images, and that of confocal images, is that only co-
localization of receptors can be suggested rather than 
true interactions. However, in combination with donor 
lifetime determinations, we could conclude whether the 
dimerization of EGFR/HER2 has indeed occurred (Figure 
2A). 
We also validated our assay in another HER2 positive 
breast cell lines SKBr3 cells treated with different targeted 
therapies (Figure 3A). We showed that Iressa decreased 
basal EGFR/HER2 dimerization as shown by an increase 
of donor lifetime compared to basal level (Figure 3A 
and 3B). Pertuzumab specifically blocks dimerization of 
HER2 by binding to domain II and sterically preventing 
association with other receptors [19], and thus is an ideal 
control to validate our assay. As seen in figure 3A, and 
supported by immunoprecipitation (Figure 3B), 1 hour 
pre-treatment with Pertuzumab resulted in an increase in 
donor fluorescence lifetime, returning the lifetime to be 
in line with the donor alone control lifetime. This implies 
that dimerization is prevented between EGFR and HER2, 
which is consistent with the mode of action.
In the EGFR positive A431 cell line, a mouse 
anti-EGFR antibody was used as the primary antibody, 
with specific anti-mouse secondary antibody coupled to 
Alexa488 and anti-rabbit HER2 primary antibody coupled 
with an Alexa546-secondary anti-rabbit antibody (Figure 
1). Figure 3D showed that A431 cells stained with donor 
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Figure 3: Validation of the EGFR/HER2 dimerization assay in relation to targeted therapies in HER2-positive and 
EGFR-positive cell lines.
A. SKBR3 cells were pre-treated with Iressa (1uM, 1h) and pertuzumab (1µg/ml, 1h) before being fixed for FRET experiments (see 
Methods). Changes in fluorescence lifetime of the different conditions are shown (n=15-20 for each condition). B. SKBR3 cells were 
treated with either 1 µM Iressa or 1µg/ml pertuzumab (2C4) for 1 hour before subjected to immunoprecipitation for EGFR and blotted for 
EGFR (lower panels) and HER2 (upper panels). C. A431 cells were stimulated with 500 ng/ml (HIGH) or 100 ng/ml (LOW) EGF for 10 
min or pre-treated with Iressa treatment for 1 hour at 5 µM (HIGH) or 1 µM (LOW) before subjected to immunoprecipitation for HER2 
and blotted for EGFR (upper panels) and HER2 (lower panels). D. A431 cells were treated with the same conditions as C before being fixed 
for FRET experiments. Dose dependent changes in lifetime for EGF and Iressa treated A431 cells are shown.Oncotarget 2011; 2:  728 - 736 732 www.impactjournals.com/oncotarget
and acceptor compared to donor alone gave significantly 
lower  lifetimes,  indicative  of  the  basal  EGFR/HER2 
dimerization in these cells (Figure 3C and 3D). To 
show that our assay is sensitive to detect the changes in 
EGFR/HER2 dimerization, we stimulated the cells with 
increased doses of EGF and assessed the donor lifetimes. 
Figure 3D shows that application of a low dose of EGF 
produces a smaller decrease in donor lifetime compared to 
the higher dose. The converse was shown to be true with 
increasing doses of Iressa, which decreased EGFR/HER2 
dimerization (Figure 3D). These changes in fluorescence 
lifetime correspond to dimerization as assessed by 
immunoprecipitation (Figure 3C), thus demonstrating the 
sensitivity of our assay in detecting changes in EGFR/
HER2 dimerization in response to different doses of 
ligand stimulation and drug treatment. 
To assess whether we could apply the assay to 
assess EGFR/HER2 dimerization in TMAs, we needed 
to  demonstrate  its  sensitivity  to  detect  EGFR/HER2 
dimerization changes in paraffin-embedded cell pellets. 
Thus, we applied the assay to A431 paraffin-embedded 
cell pellets of different pre-treatment conditions. We 
performed the assay using anti-EGFR antibody as primary 
antibody with the correct secondary labeled antibody as 
the FRET donor. The decrease in fluorescence lifetime 
for the donor and acceptor control sample suggested a 
degree  of  basal  dimerization,  which  was  significantly 
increased when treated with EGF (Figure 4A). However, 
when  treated  with  pertuzumab  (2C4),  the  fluorescence 
lifetime was seen to increase, in a manner similar to 
that in fixed cell experiment samples (Figure 4A). The 
EGFR/HER2  dimerization  patterns  correlated  with  the 
immunoprecipitation results (Figure 4B). As can be seen 
from the fluorescence images, we could only conclude 
whether EGFR receptors (upper panels, green) co-
localized with HER2 receptors (lower panels, yellow) 
without the lifetime data (Figure 4C). However, our FRET 
assay could detect changes in EGFR/HER2 dimerization 
(Figure 4A). In combination with the fluorescence images, 
we could detect HER receptor dimerization at cellular 
Figure 4: Further validation of the EGFR/HER2 dimerization assay in paraffin-embedded cell pellets.
A. A431 cells were stimulated with 100 ng/ml EGF for 10 min or pre-treated with1 µg/ml pertuzumab for 1 hour before being paraffin-
embedded for FRET experiments (see Methods). The fluorescence lifetime changes for each condition are shown (n=12-15 for each 
condition) B. Co-immunoprecipitation of EGFR and HER2 on A431 cells after the same treatment as described in A. C. Fluorescence 
intensity images of EGFR (upper panels) and HER2 (lower panels) for A431 cell pellets pre-treated with 100 ng/ml EGF for 10 min or 1µg/
ml  pertuzumab for 1 hour.Oncotarget 2011; 2:  728 - 736 733 www.impactjournals.com/oncotarget
level in paraffin-embedded cell pellets.
DISCUSSION
Here, we present a proof-of-principle study 
demonstrating that we could use a pair of secondary 
antibodies from different species, conjugated to a pair 
of  suitable  FRET  flurophores  to  assess  EGFR/HER2 
dimerization in human cell lines. This assay could be used 
to assess other HER dimerization pairings by changing the 
primary antibodies while using the same pair of flurophore-
conjugated secondary antibodies. We demonstrated the 
sensitivity and specificity of the assay in detecting EGFR/
HER2 dimerization in cell lines stimulated or treated with 
different doses of ligands and drugs. Most importantly, 
the assay is potentially applicable to tissue microarrays, 
as demonstrated by its effectiveness in paraffin-embedded 
cell pellet preparations. This will allow the dimerization 
states of tumor cells to be assessed in-situ. Thus, the assay 
can be assessed for its prognostic and predictive values in 
a clinical setting. 
It has been claimed that assays other than FRET have 
the ability to assess protein interaction and specifically 
HER dimerization. These are based on the ligation 
of proteins, including Vera Tag [20] and Proximity 
Ligation Assay (PLA), which utilized DNA ligation [21]. 
However, none of these techniques can truly prove protein 
interaction although they can suggest it. Ligation assays 
can give positive results at a distance between substrates 
of 30-40 nm, which we would argue is very conclusive for 
confirming co-localization but not dimerization. Among 
all the techniques however, FRET is regarded as the gold 
standard technique to assess protein interaction since the 
distance between the determinants is <10 nm rather than 
30-40 nm for both Vera Tag and proximity ligation assays 
[20-22]. Although there are many ways of determining 
FRET, methods based on the use of FLIM are the most 
sensitive in their ability to determine small changes in 
interaction distance and can thus be used as the basis for 
highly sensitive assays [22, 23]. The inverse sixth power 
distance dependence of FRET confers sensitivity to this 
assay, and the Förster Distance, at which half maximal 
FRET  efficiency  occurs,  is  typically  ∼5 nm [22, 23]. 
FRET induced changes in fluorescence lifetime are thus 
likely to represent direct interaction between receptors 
and have the potential advantage of accurately reflecting 
the dimerization of the receptors. It could be argued that 
by using the secondary antibody technique, we have 
increased  the  distance  between  the  fluorophores  and 
interfere with their interaction. This will decrease FRET 
efficiency and thus reduce the assay sensitivity. Therefore, 
it is possible that an even greater FRET efficiency would 
have been observed if primary conjugation was used. 
However, we have demonstrated our assay to be sensitive 
and specific in assessing EGFR/HER2 dimerization assay 
in various cell lines. Furthermore, the secondary antibody 
technique has the additional advantage of lower cost and 
thus potentially wider application to assess various protein 
interactions, compared with the primary conjugation 
approach.
Using the FRET technique, we are able to image the 
FRET process in single cells, establishing heterogeneity 
within the sample and are therefore able to identify trends, 
which might otherwise be overlooked in techniques that 
combine protein from many cells for analysis. Further 
to this, heterogeneity in dimerization within a single cell 
can be identified and thus the potential exists to explore 
the role of cellular compartmentalization HER signaling, 
which has been demonstrated to have great significance in 
acquired resistance to targeted therapies [24]. We believe 
that this assay has the potential to act as a prognostic 
test in HER2 and EGFR positive breast cancer although 
much more validation work is required. For example, it 
is well known that fluorescence lifetimes are affected by 
a multitude of factors (e.g. temperature, pH, oxygenation 
status etc.) [22, 23] and these may become limiting when 
small FRET-induced lifetime changes are to be determined. 
In the experiments described here this does not seem to 
be the case as experimental and preparation conditions 
were tightly controlled. Furthermore, application to 
paraffin-embedded patient tissue material remains to be 
validated; it may be challenging due to the presence of 
other fluorophores (e.g. endogenous auto-fluorescence), 
but the use of FRET fluorophores in the far-red portion 
of the spectrum may alleviate this. Suitably sensitive 
single photon counting detectors operating in the far-red 
are becoming available and could thus be applied. These 
assays may allow us to answer some of the unresolved 
questions regarding the unpredictable outcome of the 
currently available targeted treatments, such as Herceptin, 
and the role of HER dimerization in drug resistance.
MATERIALS AND METHODS
Materials and Cell Lines
A431 and SKBR3 cells were purchased form Cancer 
Research UK (CR-UK) and cultured in Dulbecco’s 
Modified Eagle Medium (DMEM) with 10% fetal bovine 
serum and antibiotics. BT474 cells were cultured in 
Roswell Park Memorial Institute Medium (RPMI) with 
10% fetal bovine serum and antibiotics. For these cells, 
10μg/ml insulin was added to the medium when the cells 
were passaged. F4-IgG1, a mouse monoclonal antibody 
recognizing the cytoplasmic domain of EGFR, was 
obtained from CRUK London Research Institute. Anti-
HER2 antibodies recognizing the intracellular residues 
were obtained from Cell Signaling Technology. Mouse 
and rabbit secondary antibodies conjugated to Alexa488 
or Alexa546 were purchased from Invitrogen. HER Oncotarget 2011; 2:  728 - 736 734 www.impactjournals.com/oncotarget
ligands, EGF and heregulin were purchased from Sigma 
Aldrich. Gefitinib (Iressa) was purchased from Tocris and 
pertuzumab was kindly provided by Roche. 
Förster Resonance Energy Transfer experiments
Approximately, 30,000 cells were seeded onto cover 
slips in a 24-well plate and left to settle overnight. Cells 
were treated with drugs or ligands for specific times at 
37 °C in culture media. After treatment, the staining 
protocol was performed at room temperature. Cells were 
washed with PBS and fixed with 4% paraformaldehyde 
(Pierce) in PBS for 10 minutes, then permeabilized 
with 0.2% Triton X-100 (Sigma-Aldrich) in PBS for 5 
minutes before treatment for 10 minutes with 1 mg/ml 
sodium borohydride (Sigma-Aldrich) in PBS to quench 
the background fluorescence. Between steps, cells were 
washed twice with PBS. After quenching the background 
fluorescence, a blocking step was performed for 1 hour 
using 1% BSA (Sigma-Aldrich) in PBS. After blocking, 
primary antibodies (1:200 in blocking buffer) were added 
and allowed to bind for 2.5 hours. Cells were washed 
twice with PBS and Alexa-488 or Alexa-546 conjugated 
secondary antibodies (mouse or rabbit) (1:400 in blocking 
buffer) added for 90 minutes. Cells were washed twice 
with PBS and twice with water before mounting the 
cover slips on a microscope slide using Fluoromount-G 
(Southern Biotech).
For the cell pellet studies, 107 A431 cells were 
embedded  in  paraffin.  Embedded  pellets  were  sliced 
by microtome and de-waxed. Antigen retrieval was 
performed, after which the protocol was used as described 
above. 
Fluorescence Lifetime Microscopy (FLIM)
FLIM  and  wide  field  fluorescence  imaging  were 
performed using a custom-built inverted microscope 
system operating in the single-photon excitation regime. 
FLIM was performed with excitation from a pulsed (∼4 
ps pulse width) super continuum laser source (SC450-M, 
Fianium Ltd., UK) operating at a repetition rate of 80 MHz 
and an optical filter set consisting of an excitation filter 
(Semrock FF01-470/22), dichromatic reflector (Semrock 
FF495Di02)  and  an  emission  filter  (Semrock  FF01-
520/35) and a custom built laser scanning system. Emitted 
fluorescence light from the sample was collected through 
the emission filter by a photomultiplier tube (PMH-100-
0, Becker & Hickl GmbH, Germany) in the de-scanned 
laser path and fluorescence lifetime information collected 
by a time-correlated single photon counting PCI board 
(SPC830, Becker & Hickl GmbH, Germany). Wide field 
fluorescence images were obtained with illumination from 
a metal halide arc lamp (Lumen200, Prior Ltd., UK) and 
detection with a 1344 x 1024 pixel CCD camera (ORCA-
ER, Hamamatsu Photonics) at 160 nm/pixel resolution. 
To image Alexa 488 fluorescence a ‘FITC’ filter set was 
used (Excitation: 465-495 nm, Emission: 515-555 nm) 
and to image Alexa 546 a ‘TRITC’ filter set was used 
(Excitation: 528-552 nm, Emission 578-632 nm). The 
sample was illuminated and imaged through a 40x, 1.3 NA 
objective lens (Nikon S Fluor oil) in an epi-illumination 
configuration. For FRET analysis, pixel-by-pixel lifetime 
determination  was  utilised.  The  FLIM  images  were 
obtained  and  the  outputs  files  consist  of  all  the  fitting 
parameters recorded for each image. These data can be 
analyzed to produce distinct lifetimes or a distribution of 
lifetimes across the image. The secondary conjugation 
preparation  gives  two  separate  fluorescence  lifetimes. 
Thus, a bi-exponential fluorescence model was used to fit 
the data using in-house exponential fitting software (TRI2) 
utilising a Levenberg-Marquardt algorithm [25], modified 
to derive the maximum likelihood estimate [25], with 
the larger value interpreted as that of the Alexa 488 dye 
(Supplementary  Figure  1).  Pseudo-colour  fluorescence 
lifetime maps were also produced using TRI2 [26] .
Immunoprecipitation
A431, BT474 and SKBR3 cells were grown to 
near  confluence  before  lysis.  Lysate  was  centrifuged 
for 10 minutes at maximum speed at 4°C and protein 
quantification  was  performed  on  the  supernatant. 
Streptavidin-coated magnetic beads (Bio-Nobile) were 
incubated with biotin-conjugated HER2 or F4 antibodies 
(Conjugation Kit, Innova Biosciences) for two hours at 
room temperature [13]. After that, the bead-antibody 
complex was incubated with supernatant containing equal 
amounts of protein for 2 hours at room temperature. Bead 
complexes were collected and washed three times with 
PBS-Tween (0.2%). Next, 50 µl of 4× SDS with 10% 
β-mercaptoethanol  was  added  to  the  bead  complexes. 
Complexes were boiled for 10 min at 95 °C to elute protein 
from the beads. Samples were run on a SDS gel at 130 V. 
Proteins were transferred to a membrane using a semi-dry 
transfer at 12V for 2 hours. Membrane was blocked with 3% 
BSA in PBS-Tween (0.2%) for 1 hour. Primary antibodies 
were administered for 3 hours at room temperature in the 
blocking solution, followed by 4 washes with 1% milk 
in PBS-Tween. Secondary antibodies were added in 5% 
milk in PBS-Tween for an hour at room temperature. Four 
washes in 1% milk in PBS-Tween were performed before 
visualizing antibodies by an enhanced chemiluminescent 
(ECL) detection system (GE Healthcare).
Statistical Analysis
Statistical analysis was performed using SPSS 
Version 18.0, including generation of box plots. ANOVA 
and the student’s T-test were used to establish statistical Oncotarget 2011; 2:  728 - 736 735 www.impactjournals.com/oncotarget
significance between the means of different conditions.
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